Cargando…

Synergy of nanodiamond–doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells

BACKGROUND: Tumor-associated macrophages (TAMs) are the most abundant stromal cells in the tumor microenvironment. Turning the TAMs against their host tumor cells is an intriguing therapeutic strategy particularly attractive for patients with immunologically “cold” tumors. This concept was mechanist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Hua-Zhen, Li, Tong-Fei, Wang, Chao, Ma, Yan, Liu, Yan, Zheng, Mei-Yan, Liu, Zhang-Jun-Yan, Chen, Jin-Bo, Li, Ke, Sun, Shi-Kuan, Komatsu, Naoki, Xu, Yong-Hong, Zhao, Li, Chen, Xiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422639/ https://www.ncbi.nlm.nih.gov/pubmed/34488792 http://dx.doi.org/10.1186/s12951-021-01017-w

Ejemplares similares

Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer
por: Yuan, Shen-Jun, et al.
Publicado: (2019)

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022)

Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer
por: Salaam, Amanee D, et al.
Publicado: (2014)

The CXCL10/CXCR3 Pathway Contributes to the Synergy of Thermal Ablation and PD-1 Blockade Therapy against Tumors
por: Xiao, Wenlu, et al.
Publicado: (2023)

Morphological transformation enhances Tumor Retention by Regulating the Self-assembly of Doxorubicin-peptide Conjugates
por: Xu, Liu, et al.
Publicado: (2020)

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas
por: Gong, Jun, et al.
Publicado: (2018)

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
por: Tu, Jingyao, et al.
Publicado: (2022)

Effect of Nanodiamond Concentration and the Current Density of the Electrolyte on the Texture and Mechanical Properties of Ni/Nanodiamond Composite Coatings Produced by Electrodeposition
por: Liu, Meihua, et al.
Publicado: (2019)

pH-Sensitive nanodiamond co-delivery of retinal and doxorubicin boosts breast cancer chemotherapy
por: Cui, Jicheng, et al.
Publicado: (2023)

PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness
por: Chen, Xiangyu, et al.
Publicado: (2023)

PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma
por: Lu, Li-Gong, et al.
Publicado: (2022)

Tumor-penetrating Peptide Conjugated and Doxorubicin Loaded T(1)-T(2) Dual Mode MRI Contrast Agents Nanoparticles for Tumor Theranostics
por: Gao, Lipeng, et al.
Publicado: (2018)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
por: Jure-Kunkel, Maria, et al.
Publicado: (2013)

Nanodiamond autophagy inhibitor allosterically improves the arsenical-based therapy of solid tumors
por: Cui, Zhifen, et al.
Publicado: (2018)

Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy
por: Yue, Chunyan, et al.
Publicado: (2018)

Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition
por: Lin, Yu-Wei, et al.
Publicado: (2017)

Cyclin G2 reverses immunosuppressive tumor microenvironment and potentiates PD-1 blockade in glioma
por: Li, Sen, et al.
Publicado: (2021)

Dynamic monitoring of serum specific tumor markers predicts the response to PD-1 blockade and prognosis of patients with malignant tumors
por: Dong, Qian, et al.
Publicado: (2021)

Intracellular Thermal Probing Using Aggregated Fluorescent Nanodiamonds
por: Wu, Tianli, et al.
Publicado: (2021)

CaCO(3) powder-mediated biomineralization of antigen nanosponges synergize with PD-1 blockade to potentiate anti-tumor immunity
por: Su, Runping, et al.
Publicado: (2023)

Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation
por: Zhu, Zhi-feng, et al.
Publicado: (2008)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
por: Chen, Shaomeng, et al.
Publicado: (2021)

SIRPα and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma
por: Yang, Hui, et al.
Publicado: (2022)

Loss of RBMS1 promotes anti-tumor immunity through enabling PD-L1 checkpoint blockade in triple-negative breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2022)

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022)

Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades
por: Li, Jun-Yan, et al.
Publicado: (2021)

PD-L1 blockade potentiates the antitumor effects of ALA-PDT and optimizes the tumor microenvironment in cutaneous squamous cell carcinoma
por: Zeng, Qingyu, et al.
Publicado: (2022)

Functionalisation of Detonation Nanodiamond for Monodispersed, Soluble DNA-Nanodiamond Conjugates Using Mixed Silane Bead-Assisted Sonication Disintegration
por: Edgington, Robert, et al.
Publicado: (2018)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Synthesis of Inorganic Pyrophosphatase–Nanodiamond Conjugates Resistant to Calcium and Fluoride
por: Valueva, Anastasiya V., et al.
Publicado: (2020)

Fluorescent nanodiamond – hyaluronate conjugates for target-specific molecular imaging
por: Han, Hye Hyeon, et al.
Publicado: (2021)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
por: Meng, Jinyu, et al.
Publicado: (2021)

Molecular determinants of response to PD-L1 blockade across tumor types
por: Banchereau, Romain, et al.
Publicado: (2021)

En Bloc Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer
por: Yang, Yongjun, et al.
Publicado: (2021)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer
por: Zhao, Yan, et al.
Publicado: (2022)

A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer
por: Liu, Suxing, et al.
Publicado: (2021)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i3fhuoljud3tv5hcqdpph8nq9u